CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027
Candel Therapeutics (CADL) stock fell 38% after-hours after pushing back its FDA application for prostate cancer treatment to mid-2027. The company reported $203.1M in cash, expected to last until Q2 2028. Retail traders on Stocktwits remained bullish, with some suggesting the selloff could make the stock more attractive. CADL is up 48.5% year-to-date, according to the article.
How this was made
The 30-second read
Why it matters
The stock's sharp decline reflects investor reaction to the FDA timeline push and insider selling.
Market read
The news is a primary disclosure of a significant price move driven by a regulatory delay.
What to watch
Cash runway to 2028 may give the company time to address regulatory concerns.
Background
CADL reported cash of $203.1 M to fund operations into Q2 2028 and noted CEO share sales.
Ticker impact
Shares plunged 38% after-hours as the company delayed its prostate cancer FDA application to mid‑2027.
likely continued downside as investors price in the regulatory setback
A sizable after‑hours drop combined with a regulatory delay is a fresh, material catalyst.
Market effects
Biotech sector may see heightened scrutiny on FDA timelines.
US biotech investors could reassess risk exposure.
Limited to CADL and peers; no broad market effect.
Counterpoint
The delay could allow more data collection, potentially improving eventual approval odds.
Key entities
- companyCADL
Biotech firm developing prostate cancer therapy.
